Citadel Advisors
CALT

Citadel Advisors’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Citadel Advisors’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,500
Closed -$331K – 15546
2024
Q2 		$331K Buy
8,500
+7,000
+467% +$192K ﹤0.01% 8935
2024
Q1 		$32.5K Sell
1,500
-7,600
-84% -$169K ﹤0.01% 12618
2023
Q4 		$235K Buy
9,100
+6,400
+237% +$120K ﹤0.01% 9635
2023
Q3 		$49.3K Sell
2,700
-2,900
-52% -$50.2K ﹤0.01% 11775
2023
Q2 		$87.9K Sell
5,600
-14,900
-73% -$314K ﹤0.01% 11121
2023
Q1 		$491K Sell
20,500
-11,100
-35% -$222K ﹤0.01% 8365
2022
Q4 		$554K Buy
31,600
+4,100
+15% +$66.1K ﹤0.01% 8030
2022
Q3 		$415K Buy
+27,500
New +$479K ﹤0.01% 8881
2022
Q2 		– Sell
-10,300
Closed -$191K – 14394
2022
Q1 		$191K Sell
10,300
-8,000
-44% -$160K ﹤0.01% 11596
2021
Q4 		$453K Buy
+18,300
New +$368K ﹤0.01% 9938

Other funds holding CALT

CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MTIC
Missouri Trust & Investment Company Springfield, Missouri $341M AUM 17.31% 1-Year Est. Return

Citadel Advisors's CALT Position: Q2 2024 in Review

Citadel Advisors sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q2 2024, closing a stake of 14,594 shares — an estimated $401K sold.

Citadel Advisors first reported a position in CALT in Q2 2020 and held it in 7 quarters. The position peaked at $1.48M in Q2 2020. 18 funds tracked by Wall St. Rank hold CALT as of Q2 2024.

  • Citadel Advisors reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 14,594 Calliditas Therapeutics AB American Depositary Shares shares in Q2 2024, an estimated $401K.
  • Citadel Advisors first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2020 and held it in 7 quarters.
  • Citadel Advisors's Calliditas Therapeutics AB American Depositary Shares position peaked at $1.48M in Q2 2020.
  • 18 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.